Original report · translated from Chinese
The 12th China (Shanghai) International Technology Fair (CSITF) was held at the Shanghai World Expo Exhibition and Convention Center. Innogen showcased efsubaglutide alfa and received an Advanced Consumer and Health Technology Project Award. The company attributed the recognition to the innovation, clinical value and manufacturing achievements of what it describes as Asia’s first human-derived ultra-long-acting GLP-1 receptor agonist for metabolic disease.
CSITF is China’s first national professional exhibition centred on technology display and trade, providing a forum for advanced technology exchange, research translation and industrial cooperation. Efsubaglutide alfa is an internally developed Category 1 innovative medicine supported by China’s 13th Five-Year Plan Major New Drug Development program. It is approved for type 2 diabetes in the Chinese mainland and Macao, China, and is included in the National Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Drug List (2025).
Focused on metabolic drug development and commercialisation, Innogen draws on the characteristics of Chinese patient populations while addressing unmet needs internationally. It is building a pipeline around efsubaglutide alfa and pursuing clinical development in obesity, MASH and other indications. In overweight and obesity, it is assessing potential applications in weight management, body-fat composition and metabolic fat deposition.
Doses associated with the ENLIGHT results
The ADA 2026 abstract reports 18-week weight reductions of 10.58% with 20 mg once weekly and 9.70% with 20 mg every two weeks. Other weekly doses were also studied, but these figures apply to those two dose groups. The obesity indication and these dosing regimens remain investigational.
In the Chinese Phase IIb overweight/obesity study, 18 weeks of treatment including titration and maintenance reduced body weight by 10.58% with weekly dosing and 9.70% with dosing every two weeks. The article reports that weight loss was mainly fat rather than muscle, with a 45.3% increase in muscle-to-fat ratio. Liver fat fell by up to approximately 52% in selected groups. The article interprets these results as a basis for further research into fat reduction, muscle preservation and abnormal fat accumulation. The findings were presented at the 86th American Diabetes Association Scientific Sessions in 2026.
The company reported progress in global multicentre trials for obesity-related indications, with the Australian Phase II study investigating a once-every-four-weeks regimen and further potential clinical applications.
Innogen views the award as recognition of its technical innovation, clinical work and industrial development. With metabolic disease a major public-health concern, the company continues to focus on clinical needs. It plans to advance efsubaglutide alfa across indications and international registration, develop follow-on products such as ultra-long-acting hydrogel formulations, expand its pipeline and deepen domestic and international collaborations. Its stated aim is to improve public health through high-quality original medicines and contribute to the development of China’s biopharmaceutical industry.
Note: Efsubaglutide alfa’s currently approved indication is type 2 diabetes. Obesity and weight-loss indications remain under clinical investigation and have not received marketing approval. This content communicates company research developments and industry information; it is not a pharmaceutical advertisement, treatment recommendation or promise of efficacy. Prescription medicines should be purchased with a physician’s prescription and used under medical supervision.
About Innogen
Founded in 2014, Innogen (HK.2591) is a biopharmaceutical company focused on developing and commercialising innovative medicines for metabolic diseases. Its internally developed pipeline covers indications including type 1 diabetes (T1D), obesity, metabolic dysfunction-associated steatohepatitis (MASH) and Alzheimer’s disease (AD), with international intellectual-property rights and a global patent strategy. Its core product, efsubaglutide alfa, is an internally developed, next-generation human-derived ultra-long-acting GLP-1 receptor agonist approved for type 2 diabetes in the Chinese mainland and Macao, China. It is included in the National Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Drug List (2025). The product has entered international development and registration, with the aim of providing better treatment options to patients worldwide. For more information, visit www.innogenpharm.com.